InvestSMART

TrivarX Ltd (ASX:TRI)

ALERT: Price-sensitive ASX Announcement for TRI
Current share price for TRI : $0.012 -0.008 (-40%)+
Announcement
Release
30 Jan 2026 8:24AM
Price at Release
$0.020
Full Release
download
Summary
During the quarter ending December 2025, TrivarX Limited completed a significant clinical trial for screening Major Depressive Episodes in veterans using their innovative single-lead ECG algorithm, achieving notable sensitivity and specificity. The company also expanded its technological reach by acquiring the Stabl-Im platform for neuro-oncology diagnostics, which promises early and non-invasive detection of brain tumors. Financially, TrivarX reported a cash balance of $3.47 million, supported by a successful $4.2 million placement to bolster its diagnostic and development programs. Additionally, corporate changes included the resignation of Non-Executive Director John Mathias.
Key Points
  • TrivarX completed a clinical trial to screen for Major Depressive Episode (cMDE) in veterans using a single-lead ECG algorithm.
  • The trial, conducted with the US Veterans Affairs, showed high sensitivity and specificity, validating the ECG algorithm.
  • TrivarX acquired Stabl-Im technology, expanding its portfolio into neuro-oncology imaging.
  • The Stabl-Im platform uses MRI and stable isotope labelling for early detection of active tumour growth.
  • Financial report shows cash at bank of $3.47m at the end of December 2025.
  • Payments of $1,000 were made to related parties during the quarter.
  • TrivarX secured $4.2 million in funding for advancing diagnostic platforms and development activities.
  • John Mathias resigned as Non-Executive Director effective 31 December 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.